{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:40:22Z","timestamp":1784756422258,"version":"3.55.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Chronisch rheumatische Erkrankungen sind mit einem erh\u00f6hten Risiko f\u00fcr kardiovaskul\u00e4re Erkrankungen assoziiert, die signifikant zu einer erh\u00f6hten Morbidit\u00e4t und Mortalit\u00e4t beitragen. Obwohl internationale Empfehlungen bereits existieren, fehlen konkrete Handlungsanleitungen f\u00fcr die klinische Praxis, auch aufgrund heterogener Evidenz und noch nicht vollst\u00e4ndig gekl\u00e4rter Pathomechanismen der kardiovaskul\u00e4ren Ereignisse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel<\/jats:title>\n                    <jats:p>Das Ziel war die Erstellung eines Expertenkonsensus, um praxisnahe Empfehlungen zur Pr\u00e4vention, Screening und zum Management des erh\u00f6hten kardiovaskul\u00e4ren Risikos bei rheumatoider Arthritis, Psoriasisarthritis und Spondyloarthritis zu formulieren.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methoden<\/jats:title>\n                    <jats:p>Zwischen 2023 und 2025 arbeiteten 21\u00a0Expert*innen aus verschiedenen Fachrichtungen (Rheumatologie, Kardiologie, Radiologie, Nephrologie, Endokrinologie) im Rahmen des Arbeitskreises \u201eRheuma und Herz\u201c der \u00d6sterreichischen Gesellschaft f\u00fcr Rheumatologie und Rehabilitation. Ein strukturierter Workflow wurde in mehreren Meetings entwickelt und ein Delphi-Prozess gestartet. F\u00fcnfzig Statements wurden auf einer Likert-Skala (10\u00a0Punkte) zur Abstimmung gebracht; schlie\u00dflich haben nach einer \u00dcberarbeitung alle Statements eine Zustimmung von &gt;\u202f90\u202f% erreicht. Nach Abschluss des Prozesses wurde der Workflow in ein Konsensuspapier \u00fcberf\u00fchrt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Das Gremium schl\u00e4gt ein dreiphasiges Modell der kardiovaskul\u00e4ren Versorgung vor. Phase\u00a01 (Erstdiagnose einer rheumatischen Erkrankung) legt den Schwerpunkt auf das rasche Erreichen einer Remission, die Ber\u00fccksichtigung kardiovaskul\u00e4rer Effekte antirheumatischer Therapien sowie eine fr\u00fchzeitige Lebensstilberatung. Die kardiovaskul\u00e4ren Profile antirheumatischer Medikamente werden in einer Heat-Map zusammengefasst. Phase\u00a02 (rheumatische Erkrankung mit niedriger Krankheitsaktivit\u00e4t oder in Remission) konzentriert sich auf ein systematisches kardiovaskul\u00e4res Risikoscreening ab einem Alter von \u2265\u202f40\u00a0Jahren unter Verwendung von SCORE2 oder SCORE2-OP mit einem krankheitsspezifischen Multiplikationsfaktor von 1,5\u00a0f\u00fcr RA, PsA und bei radiographischer axialer SpA. Die Patientinnen und Patienten werden gem\u00e4\u00df den von der ESC definierten Risikokategorien stratifiziert, mit definierten Upgrade-Kriterien. Phase\u00a03 (erweiterte Diagnostik und Prim\u00e4rpr\u00e4vention) verkn\u00fcpft die Risikokategorien mit LDL-Cholesterin-Zielwerten sowie einer angepassten Diagnostik mit dem Ziel der fr\u00fchzeitigen Erkennung von Atherosklerose, Arrhythmien und Herzinsuffizienz. Bei niedrigem Atheroskleroserisiko sollte eine Blutdruckmessung erfolgen, bei moderatem Risiko zus\u00e4tzlich eine Karotissonographie und bei hohem oder sehr hohem Risiko zus\u00e4tzlich ein EKG. Zum Screening auf Herzinsuffizienz wird eine liberale Bestimmung von NT-proBNP empfohlen; bei erh\u00f6hten Werten oder spezifischen Fragestellungen sollte eine gezielte Echokardiographie durchgef\u00fchrt werden. Ein opportunistisches Screening mittels Pulspalpation wird ebenfalls f\u00fcr Patientinnen und Patienten mit erh\u00f6htem Risiko f\u00fcr Vorhofflimmern empfohlen. Das EKG oder elektronische Devices k\u00f6nnen Hinweise auf Arrhythmien und Erregungsleitungsst\u00f6rungen liefern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Fazit<\/jats:title>\n                    <jats:p>Dieser Konsensus bietet einen strukturierten, krankheitsspezifisch angepassten und pragmatischen Ansatz f\u00fcr das Management des kardiovaskul\u00e4ren Risikos bei RA, PsA und SpA. Durch die Integration der Kontrolle der Grunderkrankung, der Risikostratifizierung und einer ma\u00dfgeschneiderten Diagnostik zielt er darauf ab, die fr\u00fchzeitige Erkennung und Pr\u00e4vention kardiovaskul\u00e4rer Komorbidit\u00e4ten in der rheumatologischen Praxis zu verbessern.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00508-026-02718-8","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:18:57Z","timestamp":1775132337000},"page":"49-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Konsensus-Statement der \u00d6sterreichischen Gesellschaft f\u00fcr Rheumatologie und Rehabilitation zum Management des erh\u00f6hten kardiovaskul\u00e4ren Risikos bei rheumatoider Arthritis, Psoriasisarthritis und Spondyloarthritis","Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis"],"prefix":"10.1007","volume":"138","author":[{"given":"Boris","family":"Lindner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Ausserwinkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Siess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hintenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Komposch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Lanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Lechner-Radner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gersina","family":"Rega-Kaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reinhart-Mikocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"St\u00f6gerer-Lanzenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"10354","key":"2718_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad\u00a0N, Verbeke\u00a0G, Molenberghs\u00a0G, et\u00a0al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. The Lancet. 2022;400(10354):733\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(22)01349-6.","journal-title":"The Lancet"},{"issue":"3","key":"2718_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/BOR.0000000000001004","volume":"36","author":"E Park","year":"2024","unstructured":"Park\u00a0E, Bathon\u00a0J. Cardiovascular complications of rheumatoid arthritis. Curr Opin Rheumatol. 2024;36(3):209\u201316. https:\/\/doi.org\/10.1097\/BOR.0000000000001004.","journal-title":"Curr Opin Rheumatol"},{"key":"2718_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20982837","author":"ML Ladehesa-Pineda","year":"2020","unstructured":"Ladehesa-Pineda\u00a0ML, Arias de la Rosa\u00a0I, L\u00f3pez Medina\u00a0C, et\u00a0al. Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2020; https:\/\/doi.org\/10.1177\/1759720X20982837.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"2718_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00508-024-02392-8","volume":"137","author":"M Ausserwinkler","year":"2025","unstructured":"Ausserwinkler\u00a0M, Gensluckner\u00a0S, Voelkerer\u00a0A, et\u00a0al. Genetic relationship between rheumatoid arthritis and cardiovascular diseases: A systematic review of Mendelian randomization studies. Wien Klin Wochenschr. 2025;137(9):272\u20138. https:\/\/doi.org\/10.1007\/s00508-024-02392-8.","journal-title":"Wien Klin Wochenschr"},{"key":"2718_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05781-4","author":"M Ausserwinkler","year":"2025","unstructured":"Ausserwinkler\u00a0M, Gensluckner\u00a0S, Frey\u00a0V, et\u00a0al. Cerebrovascular risk in rheumatoid arthritis patients: insights from carotid artery atherosclerosis in the Paracelsus 10,000 study. Rheumatol Int. 2025; https:\/\/doi.org\/10.1007\/s00296-024-05781-4.","journal-title":"Rheumatol Int"},{"issue":"1","key":"2718_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2016","unstructured":"Agca\u00a0R, Heslinga\u00a0SC, Rollefstad\u00a0S, et\u00a0al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2016;76(1):17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2718_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/joa3.12995","volume":"40","author":"V Jaiswal","year":"2024","unstructured":"Jaiswal\u00a0V, Roy\u00a0P, Ang\u00a0SP, et\u00a0al. Association between rheumatoid arthritis and atrial fibrillation: A systematic review and meta-analysis. J\u00a0Arrhythm. 2024;40(2):203\u201313. https:\/\/doi.org\/10.1002\/joa3.12995.","journal-title":"J Arrhythm"},{"key":"2718_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014661","author":"MJ Ahlers","year":"2020","unstructured":"Ahlers\u00a0MJ, Lowery\u00a0BD, Farber-Eger\u00a0E, et\u00a0al. Heart failure risk associated with rheumatoid arthritis\u2013related chronic inflammation. J\u00a0Am Heart Assoc. 2020; https:\/\/doi.org\/10.1161\/JAHA.119.014661.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2718_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/ard-2022-223315","volume":"82","author":"N Conrad","year":"2023","unstructured":"Conrad\u00a0N, McInnes\u00a0IB, McMurray\u00a0JJV, Sattar\u00a0N. Patients with a\u00a0range of rheumatic diseases are at increased risk of cardiovascular disorders towards a\u00a0re-evaluation of the European League against Rheumatism (EULAR)\u2019s recommendations for cardiovascular risk management? Ann Rheum Dis. 2023;82(4):457\u20139. https:\/\/doi.org\/10.1136\/ard-2022-223315.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2718_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s10067-023-06655-z","volume":"42","author":"R Hintenberger","year":"2023","unstructured":"Hintenberger\u00a0R, Affenzeller\u00a0B, Vladychuk\u00a0V, Pieringer\u00a0H. Cardiovascular risk in axial spondyloarthritis\u2014a systematic review. Clin Rheumatol. 2023;42(10):2621\u201333. https:\/\/doi.org\/10.1007\/s10067-023-06655-z.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2718_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos\u00a0GC, Vedder\u00a0D, Houben\u00a0E, et\u00a0al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768\u201379. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221733.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2718_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00296-020-04616-2","volume":"40","author":"AI Venetsanopoulou","year":"2020","unstructured":"Venetsanopoulou\u00a0AI, Pelechas\u00a0E, Voulgari\u00a0PV, Drosos\u00a0AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020;40(8):1181\u201391. https:\/\/doi.org\/10.1007\/s00296-020-04616-2.","journal-title":"Rheumatol Int"},{"issue":"3","key":"2718_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova\u00a0E, Crowson\u00a0CS, Kremers\u00a0HM, et\u00a0al. Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482\u20137. https:\/\/doi.org\/10.1136\/ard.2010.135871.","journal-title":"Ann Rheum Dis"},{"issue":"SI3","key":"2718_CR14","doi-asserted-by":"publisher","first-page":"SI237","DOI":"10.1093\/rheumatology\/kead307","volume":"62","author":"J Lewis","year":"2023","unstructured":"Lewis\u00a0J, \u00d6st\u00f6r\u00a0AJK. The prevalence and impact of polypharmacy in rheumatology. Rheumatology. 2023;62(SI3):SI237\u2013SI41. https:\/\/doi.org\/10.1093\/rheumatology\/kead307.","journal-title":"Rheumatology (United Kingdom)"},{"key":"2718_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70066","author":"S Benamar","year":"2025","unstructured":"Benamar\u00a0S, Lukas\u00a0C, Daien\u00a0C, et\u00a0al. Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study. Arthritis Care Res. 2025; https:\/\/doi.org\/10.1002\/acr2.70066.","journal-title":"ACR Open Rheumatol"},{"key":"2718_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152504","author":"DA Pappas","year":"2024","unstructured":"Pappas\u00a0DA, Reed\u00a0G, Kane\u00a0K, et\u00a0al. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients. Semin Arthritis Rheum. 2024; https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152504.","journal-title":"Semin Arthritis Rheum"},{"key":"2718_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.vph.2016.01.006","volume":"81","author":"GW Naerr","year":"2016","unstructured":"Naerr\u00a0GW, Rein\u00a0P, Saely\u00a0CH, Drexel\u00a0H. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol. 2016;81:22\u201330. https:\/\/doi.org\/10.1016\/j.vph.2016.01.006.","journal-title":"Vascul Pharmacol"},{"key":"2718_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0559-8","author":"DY Chen","year":"2015","unstructured":"Chen\u00a0DY, Chen\u00a0YM, Hsieh\u00a0TY, Hsieh\u00a0CW, Lin\u00a0CC, Lan\u00a0JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015; https:\/\/doi.org\/10.1186\/s13075-015-0559-8.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2718_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/ibd\/izaa258","volume":"27","author":"P Sinh","year":"2021","unstructured":"Sinh\u00a0P, Cross\u00a0R. Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(7):1107\u201315. https:\/\/doi.org\/10.1093\/ibd\/izaa258.","journal-title":"Inflamm Bowel Dis"},{"key":"2718_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106143","author":"VW Zwartkruis","year":"2020","unstructured":"Zwartkruis\u00a0VW, Groenewegen\u00a0A, Rutten\u00a0FH, et\u00a0al. Proactive screening for symptoms: A simple method to improve early detection of unrecognized cardiovascular disease in primary care. Results from the Lifelines Cohort Study. Prev Med Rep. 2020; https:\/\/doi.org\/10.1016\/j.ypmed.2020.106143.","journal-title":"Prev Med (Baltim)"},{"issue":"11","key":"2718_CR21","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett\u00a0DK, Blumenthal\u00a0RS, Albert\u00a0MA, et\u00a0al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation.NLM (Medline). 2019;140(11):e596\u2013e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678.","journal-title":"Circulation.NLM (Medline)"},{"issue":"25","key":"2718_CR22","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/eurheartj\/ehab310","volume":"42","author":"L Tokgozoglu","year":"2021","unstructured":"Tokgozoglu\u00a0L, Torp-Pedersen\u00a0C. Redefining cardiovascular risk prediction: Is the crystal ball clearer now? Eur Heart J Qual Care Clin Outcomes. 2021;42(25):2468\u201371. https:\/\/doi.org\/10.1093\/eurheartj\/ehab310.","journal-title":"Eur Heart J"},{"issue":"25","key":"2718_CR23","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/eurheartj\/ehab310","volume":"42","author":"L Tokgozoglu","year":"2021","unstructured":"Tokgozoglu\u00a0L, Torp-Pedersen\u00a0C. Redefining cardiovascular risk prediction: Is the crystal ball clearer now? Eur Heart J Qual Care Clin Outcomes. 2021;42(25):2468\u201371. https:\/\/doi.org\/10.1093\/eurheartj\/ehab310.","journal-title":"Eur Heart J"},{"issue":"8-9","key":"2718_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"2019","author":"F Mach","year":"2020","unstructured":"Mach* F. ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J Qual Care Clin Outcomes. 2020;2019(8-9):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"European Heart Journal"},{"key":"2718_CR25","doi-asserted-by":"publisher","unstructured":"Mach\u00a0F, Koskinas\u00a0KC, van LennepRoeters\u00a0JE, et\u00a0al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J Qual Care Clin Outcomes. 2025; https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","DOI":"10.1093\/eurheartj\/ehaf190"},{"issue":"39","key":"2718_CR26","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg\u00a0F, Mora\u00a0S, Stroes\u00a0ESG, et\u00a0al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J Qual Care Clin Outcomes. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"key":"2718_CR27","doi-asserted-by":"crossref","unstructured":"Tsimikas S. A\u00a0Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies.; 2017.","DOI":"10.1016\/j.jacc.2016.11.042"},{"issue":"25","key":"2718_CR28","doi-asserted-by":"publisher","first-page":"E1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy\u00a0SM, Stone\u00a0NJ, Bailey\u00a0AL, et\u00a0al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):E1082\u2013E143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"key":"2718_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102786","author":"B Hadwen","year":"2021","unstructured":"Hadwen\u00a0B, Stranges\u00a0S, Barra\u00a0L. Risk factors for hypertension in rheumatoid arthritis patients\u2013A systematic review. Autoimmun Rev. 2021; https:\/\/doi.org\/10.1016\/j.autrev.2021.102786.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2718_CR30","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/rheumatology\/ken159","volume":"47","author":"VF Panoulas","year":"2008","unstructured":"Panoulas\u00a0VF, Metsios\u00a0GS, Pace\u00a0AV, et\u00a0al. Hypertension in rheumatoid arthritis. Rheumatology. 2008;47(9):1286\u201398. https:\/\/doi.org\/10.1093\/rheumatology\/ken159.","journal-title":"Rheumatology"},{"issue":"8","key":"2718_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.echo.2020.04.021","volume":"33","author":"AM Johri","year":"2020","unstructured":"Johri\u00a0AM, Nambi\u00a0V, Naqvi\u00a0TZ, et\u00a0al. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J\u00a0Am Soc Echocardiogr. 2020;33(8):917\u201333. https:\/\/doi.org\/10.1016\/j.echo.2020.04.021.","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"6","key":"2718_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11897-024-00682-w","volume":"21","author":"A Zambrano Zambrano","year":"2024","unstructured":"Zambrano Zambrano\u00a0A, Del R\u00edo Zanatta\u00a0H, Gonz\u00e1lez Espinoza\u00a0A, et\u00a0al. Heart Failure in Rheumatoid Arthritis: Clinical Implications. Curr Heart Fail Rep. 2024;21(6):530\u201340. https:\/\/doi.org\/10.1007\/s11897-024-00682-w.","journal-title":"Curr Heart Fail Rep"},{"issue":"6","key":"2718_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11897-024-00686-6","volume":"21","author":"LB Kosyakovsky","year":"2024","unstructured":"Kosyakovsky\u00a0LB, de Boer\u00a0RA, Ho\u00a0JE. Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population. Curr Heart Fail Rep. 2024;21(6):591\u2013603. https:\/\/doi.org\/10.1007\/s11897-024-00686-6.","journal-title":"Curr Heart Fail Rep"},{"key":"2718_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00898-4","author":"M Chetrit","year":"2020","unstructured":"Chetrit\u00a0M, Khan\u00a0MA, Kapadia\u00a0S. State of the Art Management of Aortic Valve Disease in Ankylosing Spondylitis. Curr Rheumatol Rep. 2020; https:\/\/doi.org\/10.1007\/s11926-020-00898-4.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"2718_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jbspin.2010.01.001","volume":"77","author":"TM Goulenok","year":"2010","unstructured":"Goulenok\u00a0TM, Meune\u00a0C, Gossec\u00a0L, Dougados\u00a0M, Kahan\u00a0A, Allanore\u00a0Y. Usefulness of routine electrocardiography for heart disease screening in patients with spondyloarthropathy or rheumatoid arthritis. Joint Bone Spine. 2010;77(2):146\u201350. https:\/\/doi.org\/10.1016\/j.jbspin.2010.01.001.","journal-title":"Joint Bone Spine"},{"key":"2718_CR36","unstructured":"Moyer VA. Screening for Coronary Heart Disease With Electrocardiography: U.S. Preventive Services Task Force Recommendation Statement. https:\/\/annals.org"},{"issue":"25","key":"2718_CR37","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1161\/CIR.0b013e3182051bab","volume":"122","author":"P Greenland","year":"2010","unstructured":"Greenland\u00a0P, Alpert\u00a0JS, Beller\u00a0GA, et\u00a0al. 2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: Executive summary: A report of the American College of cardiology foundation\/American Heart association task force on practice guidelines. Circulation. 2010;122(25):2748\u201364. https:\/\/doi.org\/10.1161\/CIR.0b013e3182051bab.","journal-title":"Circulation"},{"issue":"9","key":"2718_CR38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/jamainternmed.2017.2649","volume":"177","author":"RS Bhatia","year":"2017","unstructured":"Bhatia\u00a0RS, Bouck\u00a0Z, Ivers\u00a0NM, et\u00a0al. Electrocardiograms in low-risk patients undergoing an annual health examination. JAMA Intern Med. 2017;177(9):1326\u201333. https:\/\/doi.org\/10.1001\/jamainternmed.2017.2649.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"2718_CR39","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1093\/rheumatology\/keaa025","volume":"59","author":"IT Cheng","year":"2020","unstructured":"Cheng\u00a0IT, Li\u00a0EK, Wong\u00a0PC, et\u00a0al. Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis - Which target should we choose? Rheumatology. 2020;59(10):2881\u201392. https:\/\/doi.org\/10.1093\/rheumatology\/keaa025.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"1","key":"2718_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.rdc.2022.08.005","volume":"49","author":"B Weber","year":"2023","unstructured":"Weber\u00a0B, Liao\u00a0KP. Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis. Rheumatic Disease Clinics of North America. 2023;49(1):165\u201378. https:\/\/doi.org\/10.1016\/j.rdc.2022.08.005.","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"7","key":"2718_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/acr2.11432","volume":"4","author":"K Yoshida","year":"2022","unstructured":"Yoshida\u00a0K, Harrold\u00a0LR, Middaugh\u00a0N, et\u00a0al. Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk. Arthritis Care Res. 2022;4(7):587\u201395. https:\/\/doi.org\/10.1002\/acr2.11432.","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"2718_CR42","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/ard-2024-225758","volume":"83","author":"E Ikdahl","year":"2024","unstructured":"Ikdahl\u00a0E, Semb\u00a0AG, Kerola\u00a0AM. No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register. Ann Rheum Dis. 2024;83(9):1226\u20137. https:\/\/doi.org\/10.1136\/ard-2024-225758.","journal-title":"Ann Rheum Dis"},{"key":"2718_CR43","doi-asserted-by":"crossref","unstructured":"Atzeni F, Rodr\u00edguez-Carrio J, Popa CD, Nurmohamed MT, Sz\u0171cs G, Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol.Nature Research. 2021;17(5):270\u2013290. https:\/\/doi.org\/10.1038\/s41584-021-00593\u20113","DOI":"10.1038\/s41584-021-00593-3"},{"issue":"6","key":"2718_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40266-019-00653-0","volume":"36","author":"AL Day","year":"2019","unstructured":"Day\u00a0AL, Singh\u00a0JA. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? Drugs Aging. 2019;36(6):493\u2013510. https:\/\/doi.org\/10.1007\/s40266-019-00653-0.","journal-title":"Drugs Aging"},{"issue":"1","key":"2718_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","volume":"82","author":"JM Gwinnutt","year":"2023","unstructured":"Gwinnutt\u00a0JM, Wieczorek\u00a0M, Balanescu\u00a0A, et\u00a0al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):48\u201356. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222020.","journal-title":"Ann Rheum Dis"},{"issue":"34","key":"2718_CR46","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"F Visseren","year":"2021","unstructured":"Visseren\u00a0F, Mach\u00a0F, Smulders\u00a0YM, et\u00a0al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J Qual Care Clin Outcomes. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"10","key":"2718_CR47","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.amjcard.2018.01.044","volume":"121","author":"YR Chen","year":"2018","unstructured":"Chen\u00a0YR, Hsieh\u00a0FI, Chang\u00a0CC, Chi\u00a0NF, Wu\u00a0HC, Chiou\u00a0HY. Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis. Am J Cardiol. 2018;121(10):1271\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2018.01.044.","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"2718_CR48","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille\u00a0C, Richer\u00a0V, Starnino\u00a0T, et\u00a0al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2718_CR49","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","volume":"17","author":"F Atzeni","year":"2021","unstructured":"Atzeni\u00a0F, Rodr\u00edguez-Carrio\u00a0J, Popa\u00a0CD, Nurmohamed\u00a0MT, Sz\u0171cs\u00a0G, Szekanecz\u00a0Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(5):270\u201390. https:\/\/doi.org\/10.1038\/s41584-021-00593-3.","journal-title":"Nat Rev Rheumatol.Nature Research"},{"issue":"1","key":"2718_CR50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/rheumatology\/kead684","volume":"64","author":"JW Kim","year":"2025","unstructured":"Kim\u00a0JW, Yoon\u00a0JS, Park\u00a0S, et\u00a0al. Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis. Rheumatology. 2025;64(1):261\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kead684.","journal-title":"Rheumatology"},{"issue":"8","key":"2718_CR51","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1136\/ard-2023-225406","volume":"83","author":"JW Kim","year":"2024","unstructured":"Kim\u00a0JW, Yoon\u00a0JS, Park\u00a0S, Kim\u00a0H, Lee\u00a0JS, Choe\u00a0JY. Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis. Ann Rheum Dis. 2024;83(8):1028\u201333. https:\/\/doi.org\/10.1136\/ard-2023-225406.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2718_CR52","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/rheumatology\/kead072","volume":"62","author":"O Fakih","year":"2023","unstructured":"Fakih\u00a0O, Desmarets\u00a0M, Martin\u00a0B, et\u00a0al. Impact of NSAIDs on 8\u2011year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: A nationwide study. Rheumatology. 2023;62(10):3317\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/kead072.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"12","key":"2718_CR53","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","volume":"80","author":"AJ Ocon","year":"2021","unstructured":"Ocon\u00a0AJ, Reed\u00a0G, Pappas\u00a0DA, Curtis\u00a0JR, Kremer\u00a0JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80(12):1522\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220577.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2718_CR54","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard-2023-224185","volume":"82","author":"H So","year":"2023","unstructured":"So\u00a0H, Lam\u00a0TO, Meng\u00a0H, Lam\u00a0SHM, Tam\u00a0LS. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: A\u00a0population-based study. Ann Rheum Dis. 2023;82(11):1387\u201393. https:\/\/doi.org\/10.1136\/ard-2023-224185.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2718_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.38210","volume":"66","author":"I Del Rinc\u00f3n","year":"2014","unstructured":"Del Rinc\u00f3n\u00a0I, Battafarano\u00a0DF, Restrepo\u00a0JF, Erikson\u00a0JM, Escalante\u00a0A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):264\u201372. https:\/\/doi.org\/10.1002\/art.38210.","journal-title":"Arthritis and Rheumatology"},{"issue":"2","key":"2718_CR56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","volume":"52","author":"S PRODANOWICH","year":"2005","unstructured":"PRODANOWICH\u00a0S, MA\u00a0F, TAYLOR\u00a0J, PEZON\u00a0C, FASIHI\u00a0T, KIRSNER\u00a0R. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J\u00a0Am Acad Dermatol. 2005;52(2):262\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2004.06.017.","journal-title":"J Am Acad Dermatol"},{"key":"2718_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152031","author":"J Xu","year":"2022","unstructured":"Xu\u00a0J, Xiao\u00a0L, Zhu\u00a0J, Qin\u00a0Q, Fang\u00a0Y, Zhang\u00a0J, et\u00a0al. Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022; https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152031.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"2718_CR58","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1136\/annrheumdis-2021-220125","volume":"80","author":"TM Johnson","year":"2021","unstructured":"Johnson\u00a0TM, Sayles\u00a0HR, Baker\u00a0JF, et\u00a0al. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1385\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220125.","journal-title":"Ann Rheum Dis"},{"key":"2718_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.703279","author":"K Hloch","year":"2021","unstructured":"Hloch\u00a0K, Dosed\u011bl\u00a0M, Duintjer Tebbens\u00a0J, et\u00a0al. Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment. Front Pharmacol. 2021; https:\/\/doi.org\/10.3389\/fphar.2021.703279.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2718_CR60","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","volume":"33","author":"L Costa","year":"2014","unstructured":"Costa\u00a0L, Caso\u00a0F, Atteno\u00a0M, et\u00a0al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33(6):833\u20139. https:\/\/doi.org\/10.1007\/s10067-013-2369-1.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"2718_CR61","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille\u00a0C, Richer\u00a0V, Starnino\u00a0T, et\u00a0al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624.","journal-title":"Ann Rheum Dis"},{"key":"2718_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1439-1","author":"G Deyab","year":"2017","unstructured":"Deyab\u00a0G, Hokstad\u00a0I, Whist\u00a0JE, et\u00a0al. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Res Ther. 2017; https:\/\/doi.org\/10.1186\/s13075-017-1439-1.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2718_CR63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10067-014-2769-x","volume":"35","author":"PA MacMullan","year":"2016","unstructured":"MacMullan\u00a0PA, Madigan\u00a0AM, Paul\u00a0N, et\u00a0al. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol. 2016;35(2):447\u201355. https:\/\/doi.org\/10.1007\/s10067-014-2769-x.","journal-title":"Clin Rheumatol"},{"key":"2718_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010011","author":"S Ahmed","year":"2022","unstructured":"Ahmed\u00a0S, Jacob\u00a0B, Carsons\u00a0SE, De Leon\u00a0J, Reiss\u00a0AB. Treatment of cardiovascular disease in rheumatoid arthritis: A\u00a0complex challenge with increased atherosclerotic risk. Pharmaceuticals.MDPI. 2022; https:\/\/doi.org\/10.3390\/ph15010011.","journal-title":"Pharmaceuticals.MDPI"},{"issue":"4","key":"2718_CR65","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","volume":"60","author":"R Persson","year":"2021","unstructured":"Persson\u00a0R, Hagberg\u00a0KW, Qian\u00a0Y, Vasilakis-Scaramozza\u00a0C, Jick\u00a0S. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology. 2021;60(4):1926\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keaa683.","journal-title":"Rheumatology (United Kingdom)"},{"key":"2718_CR66","unstructured":"Alcorn N, Saunders S, Madhok R. Benefit-Risk Assessment of Leflunomide An Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing."},{"issue":"10","key":"2718_CR67","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.7150\/IJBS.93465","volume":"20","author":"X Jiang","year":"2024","unstructured":"Jiang\u00a0X, Wang\u00a0W, Lei\u00a0L, et\u00a0al. Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH\/AMPK signaling pathway. Int J Biol Sci. 2024;20(10):3725\u201341. https:\/\/doi.org\/10.7150\/IJBS.93465.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"2718_CR68","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10067-010-1425-3","volume":"29","author":"H Kellner","year":"2010","unstructured":"Kellner\u00a0H, Bornholdt\u00a0K, Hein\u00a0G. Leflunomide in the treatment of patients with early rheumatoid arthritis-results of a prospective non-interventional study. Clin Rheumatol. 2010;29(8):913\u201320. https:\/\/doi.org\/10.1007\/s10067-010-1425-3.","journal-title":"Clin Rheumatol"},{"key":"2718_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241271886","author":"JC Williams","year":"2024","unstructured":"Williams\u00a0JC, Hum\u00a0RM, Rogers\u00a0K, Maglio\u00a0C, Alam\u00a0U, Zhao\u00a0SS. Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy. Ther Adv Musculoskelet Dis. 2024; https:\/\/doi.org\/10.1177\/1759720X241271886.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"2718_CR70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10557-022-07387-z","volume":"38","author":"A Cordova Sanchez","year":"2024","unstructured":"Cordova Sanchez\u00a0A, Khokhar\u00a0F, Olonoff\u00a0DA, Carhart\u00a0RL. Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis. Cardiovasc Drugs Ther. 2024;38(2):297\u2013304. https:\/\/doi.org\/10.1007\/s10557-022-07387-z.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2718_CR71","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002867","author":"TS Sharma","year":"2016","unstructured":"Sharma\u00a0TS, Wasko\u00a0MCM, Tang\u00a0X, et\u00a0al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J\u00a0Am Heart Assoc. 2016; https:\/\/doi.org\/10.1161\/JAHA.115.002867.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2718_CR72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault\u00a0C, Combe\u00a0B, Barnetche\u00a0T, et\u00a0al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: A systematic review and meta-Analysis. Ann Rheum Dis. 2018;77(1):98\u2013103. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211836.","journal-title":"Ann Rheum Dis"},{"key":"2718_CR73","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/DDDT.S166893","volume":"12","author":"D Liu","year":"2018","unstructured":"Liu\u00a0D, Li\u00a0X, Zhang\u00a0Y, et\u00a0al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:1685\u201395. https:\/\/doi.org\/10.2147\/DDDT.S166893.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"2718_CR74","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"ASL Low","year":"2017","unstructured":"Low\u00a0ASL, Symmons\u00a0DPM, Lunt\u00a0M, et\u00a0al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(4):654\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209784.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2718_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/acr.20371","volume":"63","author":"C Barnabe","year":"2011","unstructured":"Barnabe\u00a0C, Martin\u00a0BJ, Ghali\u00a0WA. Systematic review and meta-analysis: anti-tumor necrosis factor\u00a0\u03b1 therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63(4):522\u20139. https:\/\/doi.org\/10.1002\/acr.20371.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2718_CR76","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","volume":"17","author":"F Atzeni","year":"2021","unstructured":"Atzeni\u00a0F, Rodr\u00edguez-Carrio\u00a0J, Popa\u00a0CD, Nurmohamed\u00a0MT, Sz\u0171cs\u00a0G, Szekanecz\u00a0Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(5):270\u201390. https:\/\/doi.org\/10.1038\/s41584-021-00593-3.","journal-title":"Nat Rev Rheumatol.Nature Research"},{"issue":"2","key":"2718_CR77","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","volume":"51","author":"Zsheng Yang","year":"2016","unstructured":"Yang\u00a0Zsheng, Lin\u00a0Nning, Li\u00a0L, Li\u00a0Y. The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis. Clin Rev Allergy Immunol. 2016;51(2):240\u20137. https:\/\/doi.org\/10.1007\/s12016-016-8560-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2718_CR78","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","volume":"76","author":"JJ Wu","year":"2017","unstructured":"Wu\u00a0JJ, Gu\u00e9rin\u00a0A, Sundaram\u00a0M, Dea\u00a0K, Cloutier\u00a0M, Mulani\u00a0P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor\u2011\u03b1 inhibitors versus methotrexate. J\u00a0Am Acad Dermatol. 2017;76(1):81\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.042.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2718_CR79","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","volume":"31","author":"MND Di Minno","year":"2011","unstructured":"Di Minno\u00a0MND, Iervolino\u00a0S, Peluso\u00a0R, Scarpa\u00a0R, Di Minno\u00a0G. Carotid intima-media thickness in psoriatic arthritis: Differences between tumor necrosis factor\u2011\u03b1 blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31(3):705\u201312. https:\/\/doi.org\/10.1161\/ATVBAHA.110.214585.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2718_CR80","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211032444","author":"SCW Chan","year":"2021","unstructured":"Chan\u00a0SCW, Teo\u00a0CK, Li\u00a0PH, Lau\u00a0KK, Lau\u00a0CS, Chung\u00a0HY. Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs. Ther Adv Musculoskelet Dis. 2021; https:\/\/doi.org\/10.1177\/1759720X211032444.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"2718_CR81","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/rheumatology\/kead072","volume":"62","author":"O Fakih","year":"2023","unstructured":"Fakih\u00a0O, Desmarets\u00a0M, Martin\u00a0B, et\u00a0al. Impact of NSAIDs on 8\u2011year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: A nationwide study. Rheumatology. 2023;62(10):3317\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/kead072.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"2","key":"2718_CR82","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/BOR.0000000000000999","volume":"36","author":"R Sen","year":"2024","unstructured":"Sen\u00a0R, Caplan\u00a0L, Danila\u00a0MI. Cardiovascular disease in spondyloarthritis: A narrative review of risk factors and the effect of treatments. Curr Opin Rheumatol. 2024;36(2):95\u2013107. https:\/\/doi.org\/10.1097\/BOR.0000000000000999.","journal-title":"Curr Opin Rheumatol"},{"key":"2718_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011250","author":"EM Zardi","year":"2018","unstructured":"Zardi\u00a0EM, Pipita\u00a0ME, Giorgi\u00a0C, Lichinchi\u00a0D, Zardi\u00a0DM, Afeltra\u00a0A. Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor\u2011\u03b1 antagonists and healthy matched controls. Medicine (United States). 2018; https:\/\/doi.org\/10.1097\/MD.0000000000011250.","journal-title":"Medicine (United States)"},{"issue":"5","key":"2718_CR84","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","volume":"48","author":"G Ozen","year":"2021","unstructured":"Ozen\u00a0G, Pedro\u00a0S, Michaud\u00a0K. The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J\u00a0Rheumatol. 2021;48(5):648\u201355. https:\/\/doi.org\/10.3899\/jrheum.200265.","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"2718_CR85","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"SC Kim","year":"2018","unstructured":"Kim\u00a0SC, Solomon\u00a0DH, Rogers\u00a0JR, et\u00a0al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018;48(3):399\u2013405. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.012.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2718_CR86","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40266-019-00653-0","volume":"36","author":"AL Day","year":"2019","unstructured":"Day\u00a0AL, Singh\u00a0JA. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? Drugs Aging. 2019;36(6):493\u2013510. https:\/\/doi.org\/10.1007\/s40266-019-00653-0.","journal-title":"Drugs Aging"},{"issue":"9","key":"2718_CR87","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease\u00a0PJ, Gottlieb\u00a0AB, Van Der Heijde\u00a0D, et\u00a0al. Efficacy and safety of abatacept, a T\u2011cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2718_CR88","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1084\/jem.20100155","volume":"207","author":"H Ait-Oufella","year":"2010","unstructured":"Ait-Oufella\u00a0H, Herbin\u00a0O, Bouaziz\u00a0JD, et\u00a0al. B cell depletion reduces the development of atherosclerosis in mice. J\u00a0Exp Med. 2010;207(8):1579\u201387. https:\/\/doi.org\/10.1084\/jem.20100155.","journal-title":"Journal of Experimental Medicine"},{"key":"2718_CR89","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001267","author":"PY Hsue","year":"2014","unstructured":"Hsue\u00a0PY, Scherzer\u00a0R, Grunfeld\u00a0C, et\u00a0al. Depletion of B\u2011cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J\u00a0Am Heart Assoc. 2014; https:\/\/doi.org\/10.1161\/JAHA.114.001267.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2718_CR90","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.autrev.2019.03.008","volume":"18","author":"F Ursini","year":"2019","unstructured":"Ursini\u00a0F, Ruscitti\u00a0P, Caio\u00a0GPI, Manfredini\u00a0R, Giacomelli\u00a0R, De Giorgio\u00a0R. The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A\u00a0systematic literature review. Autoimmun Rev. 2019;18(5):501\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.008.","journal-title":"Autoimmun Rev"},{"key":"2718_CR91","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2453265","volume":"2018","author":"F Cacciapaglia","year":"2018","unstructured":"Cacciapaglia\u00a0F, Anelli\u00a0MG, Rinaldi\u00a0A, et\u00a0al. Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment. Mediators Inflamm. 2018;2018:2453265. https:\/\/doi.org\/10.1155\/2018\/2453265.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"2718_CR92","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh\u00a0S, Fumery\u00a0M, Singh\u00a0AG, et\u00a0al. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res. 2020;72(4):561\u201376. https:\/\/doi.org\/10.1002\/acr.23875.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10289","key":"2718_CR93","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker\u00a0PM, Devalaraja\u00a0M, Baeres\u00a0FMM, et\u00a0al. IL\u20116 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 2021;397(10289):2060\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1.","journal-title":"The Lancet"},{"issue":"4","key":"2718_CR94","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/CIRCIMAGING.113.001193","volume":"7","author":"I Ikonomidis","year":"2014","unstructured":"Ikonomidis\u00a0I, Tzortzis\u00a0S, Andreadou\u00a0I, et\u00a0al. Increased beneft of interleukin\u20111 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619\u201328. https:\/\/doi.org\/10.1161\/CIRCIMAGING.113.001193.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"2718_CR95","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/nejmoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker\u00a0PM, Everett\u00a0BM, Thuren\u00a0T, et\u00a0al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/nejmoa1707914.","journal-title":"New England Journal of Medicine"},{"key":"2718_CR96","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.006283","author":"I Ikonomidis","year":"2017","unstructured":"Ikonomidis\u00a0I, Papadavid\u00a0E, Makavos\u00a0G, et\u00a0al. Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor\u2011a antagonism or cyclosporine in psoriasis. Circ Cardiovasc Imaging. 2017; https:\/\/doi.org\/10.1161\/CIRCIMAGING.117.006283.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2718_CR97","unstructured":"Ryan C, Craig Leonardi BcL, Krueger JG, et\u00a0al. Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events A Meta-Analysis of Randomized Controlled Trials. www.jamaarchivescme.com"},{"issue":"1","key":"2718_CR98","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand\u00a0JM, Shin\u00a0DB, Alavi\u00a0A, et\u00a0al. A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP\u2011U Trial). J\u00a0Invest Dermatol. 2020;140(1):85\u201393.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.07.679.","journal-title":"Journal of Investigative Dermatology"},{"key":"2718_CR99","doi-asserted-by":"publisher","DOI":"10.4161\/derm.23100","author":"T Tzellos","year":"2012","unstructured":"Tzellos\u00a0T, Kyrgidis\u00a0A, Trigoni\u00a0A, Zouboulis\u00a0CC. Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol. 2012; https:\/\/doi.org\/10.4161\/derm.23100.","journal-title":"Dermatoendocrinol"},{"key":"2718_CR100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/VHRM.S464471","volume":"20","author":"H Mehta","year":"2024","unstructured":"Mehta\u00a0H, Narang\u00a0T, Dogra\u00a0S, Handa\u00a0S, Hatwal\u00a0J, Batta\u00a0A. Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review. Vasc Health Risk Manag. 2024;20:215\u201329. https:\/\/doi.org\/10.2147\/VHRM.S464471.","journal-title":"Vasc Health Risk Manag"},{"key":"2718_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1353893","author":"Y Zhang","year":"2024","unstructured":"Zhang\u00a0Y, Yang\u00a0Z, Gong\u00a0J, Shi\u00a0D. Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a\u00a0meta-analysis of randomized controlled trials. Front Med. 2024; https:\/\/doi.org\/10.3389\/fmed.2024.1353893.","journal-title":"Front Med (Lausanne)"},{"key":"2718_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020318","author":"A Tsiogka","year":"2023","unstructured":"Tsiogka\u00a0A, Gregoriou\u00a0S, Stratigos\u00a0A, et\u00a0al. The Impact of Treatment with IL-17\/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and\/or Psoriatic Arthritis: A Systematic Review. Biomedicines. 2023; https:\/\/doi.org\/10.3390\/biomedicines11020318.","journal-title":"Biomedicines.MDPI"},{"key":"2718_CR103","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb\u00a0AB, Deodhar\u00a0A, McInnes\u00a0IB, et\u00a0al. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Derm Venereol. 2022; https:\/\/doi.org\/10.2340\/actadv.v102.563.","journal-title":"Acta Derm Venereol"},{"key":"2718_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03257-7","author":"A Deodhar","year":"2024","unstructured":"Deodhar\u00a0A, Blauvelt\u00a0A, Lebwohl\u00a0M, et\u00a0al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024; https:\/\/doi.org\/10.1186\/s13075-023-03257-7.","journal-title":"Arthritis Res Ther"},{"key":"2718_CR105","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman\u00a0C, Buch\u00a0MH, Dougados\u00a0M, et\u00a0al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82:119\u201329. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222259.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2718_CR106","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/nejmoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR, et\u00a0al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/nejmoa2109927.","journal-title":"New England Journal of Medicine"},{"key":"2718_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003489","author":"Y Meissner","year":"2023","unstructured":"Meissner\u00a0Y, Sch\u00e4fer\u00a0M, Albrecht\u00a0K, et\u00a0al. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open. 2023; https:\/\/doi.org\/10.1136\/rmdopen-2023-003489.","journal-title":"RMD Open"},{"issue":"5","key":"2718_CR108","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/RHU.0000000000002106","volume":"30","author":"G Citera","year":"2024","unstructured":"Citera\u00a0G, Mysler\u00a0E, Kakehasi\u00a0AM, et\u00a0al. Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients with Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study. Journal of Clinical Rheumatology. 2024;30(5):208\u201316. https:\/\/doi.org\/10.1097\/RHU.0000000000002106.","journal-title":"Journal of Clinical Rheumatology"},{"issue":"4","key":"2718_CR109","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2023","unstructured":"Aymon\u00a0R, Mongin\u00a0D, Bergstra\u00a0SA, et\u00a0al. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study). Ann Rheum Dis. 2023;83(4):421\u20138. https:\/\/doi.org\/10.1136\/ard-2023-224670.","journal-title":"Ann Rheum Dis"},{"key":"2718_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.782150","author":"E Toussirot","year":"2021","unstructured":"Toussirot\u00a0E. The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights. Front Med. 2021; https:\/\/doi.org\/10.3389\/fmed.2021.782150.","journal-title":"Front Med (Lausanne)"},{"key":"2718_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459185","author":"N Barbarroja","year":"2024","unstructured":"Barbarroja\u00a0N, L\u00f3pez-Medina\u00a0C, Escudero-Contreras\u00a0A, Arias-de la Rosa\u00a0I. Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast. Front Immunol. 2024; https:\/\/doi.org\/10.3389\/fimmu.2024.1459185.","journal-title":"Front Immunol"},{"issue":"4","key":"2718_CR112","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","volume":"61","author":"LP Vegas","year":"2022","unstructured":"Vegas\u00a0LP, Le Corvoisier\u00a0P, Penso\u00a0L, Paul\u00a0M, Sbidian\u00a0E, Claudepierre\u00a0P. Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a\u00a0nationwide cohort study. Rheumatology. 2022;61(4):1589\u201399. https:\/\/doi.org\/10.1093\/rheumatology\/keab522.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"3","key":"2718_CR113","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","volume":"61","author":"LD Ferguson","year":"2022","unstructured":"Ferguson\u00a0LD, Cathcart\u00a0S, Rimmer\u00a0D, et\u00a0al. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease - Results of the Immune Metabolic Associations in Psoriatic Arthritis study. Rheumatology. 2022;61(3):1026\u201334. https:\/\/doi.org\/10.1093\/rheumatology\/keab474.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"4","key":"2718_CR114","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","volume":"60","author":"R Persson","year":"2021","unstructured":"Persson\u00a0R, Hagberg\u00a0KW, Qian\u00a0Y, Vasilakis-Scaramozza\u00a0C, Jick\u00a0S. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology. 2021;60(4):1926\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keaa683.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"34","key":"2718_CR115","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"F Visseren","year":"2021","unstructured":"Visseren\u00a0F, Mach\u00a0F, Smulders\u00a0YM, et\u00a0al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J Qual Care Clin Outcomes. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"10459","key":"2718_CR116","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard\u00a0BG, Langsted\u00a0A. Lipoprotein(a) and cardiovascular disease. The Lancet. 2024;404(10459):1255\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(24)01308-4.","journal-title":"The Lancet"},{"issue":"3","key":"2718_CR117","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky\u00a0ML, Bajaj\u00a0A, Boffa\u00a0MB, et\u00a0al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J\u00a0Clin Lipidol. 2024;18(3):e308\u2013e19. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.001.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2718_CR118","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40119-022-00282-6","volume":"11","author":"G Renke","year":"2022","unstructured":"Renke\u00a0G, Gapanowicz\u00a0DP, Pereira\u00a0MB, et\u00a0al. Long-Term Association between Intensive Medical Treatment and the Incidence of Cardiovascular Outcomes in Patients with Dyslipidemia: an Observational Study. Cardiol Ther. 2022;11(4):575\u201387. https:\/\/doi.org\/10.1007\/s40119-022-00282-6.","journal-title":"Cardiol Ther"},{"key":"2718_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235207","author":"YM Wu","year":"2020","unstructured":"Wu\u00a0YM, Liu\u00a0CC, Yeh\u00a0CC, et\u00a0al. Hospitalization outcome of heart diseases between patients who received medical care by cardiologists and non-cardiologist physicians: A propensity-score matched study. PLoS One. 2020; https:\/\/doi.org\/10.1371\/journal.pone.0235207.","journal-title":"PLoS One"},{"issue":"10","key":"2718_CR120","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1093\/rheumatology\/keaa025","volume":"59","author":"IT Cheng","year":"2020","unstructured":"Cheng\u00a0IT, Li\u00a0EK, Wong\u00a0PC, et\u00a0al. Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis - Which target should we choose? Rheumatology. 2020;59(10):2881\u201392. https:\/\/doi.org\/10.1093\/rheumatology\/keaa025.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"1","key":"2718_CR121","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.rdc.2022.08.005","volume":"49","author":"B Weber","year":"2023","unstructured":"Weber\u00a0B, Liao\u00a0KP. Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis. Rheumatic Disease Clinics of North America. 2023;49(1):165\u201378. https:\/\/doi.org\/10.1016\/j.rdc.2022.08.005.","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"7","key":"2718_CR122","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/acr2.11432","volume":"4","author":"K Yoshida","year":"2022","unstructured":"Yoshida\u00a0K, Harrold\u00a0LR, Middaugh\u00a0N, et\u00a0al. Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk. Arthritis Care Res. 2022;4(7):587\u201395. https:\/\/doi.org\/10.1002\/acr2.11432.","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"2718_CR123","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/ard-2024-225758","volume":"83","author":"E Ikdahl","year":"2024","unstructured":"Ikdahl\u00a0E, Semb\u00a0AG, Kerola\u00a0AM. No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register. Ann Rheum Dis. 2024;83(9):1226\u20137. https:\/\/doi.org\/10.1136\/ard-2024-225758.","journal-title":"Ann Rheum Dis"},{"key":"2718_CR124","doi-asserted-by":"publisher","unstructured":"Zimerman A, Kunzler ALF, Weber BN, et\u00a0al. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025;151(20):1467\u20131476. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072756","DOI":"10.1161\/CIRCULATIONAHA.124.072756"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02718-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02718-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02718-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:19:01Z","timestamp":1775132341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02718-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":124,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2718"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02718-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.\u00a0Lindner, M.\u00a0Ausserwinkler, C.\u00a0Siess, K.\u00a0Ammerer, M.\u00a0Esposito, J.\u00a0Hermann, R.\u00a0Hintenberger, M.\u00a0Komposch, L.\u00a0Lanser, H.\u00a0Lechner-Radner, C.\u00a0Peter, G.\u00a0Rega-Kaun, D.\u00a0Reinhart-Mikocki, S.\u00a0Schedl, M.\u00a0St\u00f6gerer-Lanzenberger, J.\u00a0Thiel und A.\u00a0Niessner geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}